Turning FDA guidance into lab reality – Accelerating animal-free drug pipelines with organ-on-a-chip technology
June 23, 2025 – 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT
With the recent FDA announcement to phase out animal testing in preclinical studies, new approach methodologies (NAMs) are being adopted including computational modeling, advanced in vitro assays and organ-on-a-chip systems. After working on a decade long collaboration with the FDA, join us for an insightful webinar where two experts from Emulate will present its contribution, the approved organ-on-a-chip technology.
Join Dr. Lorna Ewart, Chief Scientific Officer and Dr. Daniel Levner, Chief Technology Officer, as they share a preview of the next-generation technology that is purpose built to stay ahead of the animal reduction mandates for toxicology testing. You will also discover how to align your IND or NDA with the new regulatory landscape, integrate Emulate solutions into existing workflows, and project a quantifiable ROI from faster, more human relevant data.
Key learning objectives
- Explore the latest guidance urging reduced animal testing and what it means for submissions
- Discover key milestones of the work between Emulate and the FDA that is securing organ-on-a-chip approvals for toxicology and other contexts of use
- Investigate how Emulate's current and upcoming platforms meet and future proof you against the FDA’s new animal reduction requirements
Who should attend?
- Individuals in fast tracking IND submissions
- Executives, lab managers, scientists and end users working in the pharma and biopharma industry
- Academics such as professors, assistant professors and post-docs
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Dr. Lorna Ewart, is Chief Scientific Officer at Emulate, steering the company’s scientific strategy and biological R&D, drawing on 20 + years in bioscience and drug safety. Prior to Emulate, at AstraZeneca she founded the Microphysiological Systems Centre of Excellence, leading industry adoption of Organ-Chips, and later ran Veroli Consulting, advising academia, biotech, and pharma on OrganChip and organoid technologies. A classically trained pharmacologist, she has 35+ publications and is a Fellow of the Royal Society of Biology and British Pharmacological Society.
Dr. Daniel Levner holds a PhD in electrical engineering and an MS in aeronautics from Stanford, and lists 70+ patents. At present, he is the Chief Technology Officer and co-founder of Emulate, where he directs development and commercialization of the OrganChips platform. Formerly a Senior Staff Scientist at Harvard’s Wyss Institute, he led the engineering team that united biology, engineering, and business to launch the technology. Dr. Levner previously collaborated with Prof. George Church on advanced diagnostics and sequencing, and earlier founded start-ups in medical diagnostics and optical telecom.
Moderator
